Find a treatment specifically created for von Willebrand disease (VWD) bleeding episodes1
As an adult living with VWD, you may share a bleeding disorder with others, but you also may have your own Deciding Factor—something that drives you to ask your healthcare provider about finding a treatment that's right for you.
The only VWD factor treatment that's manufactured without human blood or plasma.2,3
Can be used with or without recombinant FVIII as directed.1
Created specifically to treat VWD
VONVENDI® is used to treat bleeds in adults with von Willebrand disease (VWD), an inherited bleeding disorder that makes it difficult to form blood clots.1 VONVENDI is the first and only recombinant treatment for VWD, meaning it's made without using human blood.2,3 Recombinant products have virtually no risk of being exposed to disease that can be spread through contamination by infected human blood.2
VONVENDI is used in adults (age 18 years and older) diagnosed with von Willebrand disease to:
treat and control bleeding episodes
prevent excessive bleeding during and after surgery
Who should not use VONVENDI?
You should not use VONVENDI if you:
Are allergic to any ingredients in VONVENDI
Are allergic to mice or hamsters
VONVENDI Prescribing Information
Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol. 2016;9(9):825-830.
Baxalta receives FDA Approval for VONVENDI, the first and only recombinant treatment for adults affected by von Willebrand disease. Business Wire. December 8, 2015. Accessed July 9, 2020. https://www.businesswire.com/news/home/20151208006689/en/Baxalta-Receives-FDA-Approval-VONVENDIRecombinant-Treatment
You're now leaving this site
Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.